Mereo BioPharma Group plc
NASDAQ:MREOBiotechnology
+$0.03 today
- Market cap
- $51.08M
- Beta
- 0.28
- P/E (TTM)
- -1.4
- EPS (TTM)
- -$0.22
Volume 1.26M
Average 3.36M
MREO Accounts Payables
Cash effect of the change in amounts owed to suppliers; growing payables preserve cash.
Mereo BioPharma Group plcNASDAQ: MREO
Accounts Payables · Q1 FY2026 · quarter ended Mar 2026
Accounts payables growth accelerates
Q1 FY2026 accounts payables of $1.96M rose 440.6% year over year, ahead of the +226.0% change in trailing-twelve-month accounts payables. Sequentially, it rose 334.5% from the prior quarter.
Context
- Accounts payables amounted to 275.6% of revenue in FY2025.
- Accounts payables increased in 1 of the last 3 fiscal years.
- FY2025 was the lowest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +440.6% holds above the trailing-twelve-month pace of +226.0%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Accounts Payables history
USD · from the cash flow
- Latest · FY2025
- (1.38M) USD
- Year-over-year change
- -1043.8%
| Period | Period end | Accounts Payables | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (1.38M) | -1043.8% |
| FY2024 | 2024-12-31 | 146K | +111.6% |
| FY2023 | 2023-12-31 | (1.26M) | -304.7% |
| FY2022 | 2022-12-31 | 617K | — |
| FY2021 | 2021-12-31 | 0 | — |
Accounts Payables vs competitors
How MREO compares with its peers on the latest reported figures
- Peers report in different currencies, so accounts payables is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +226.0% is the 2nd highest of 7, against a peer median of -136.1%.
- Accounts payables amounts to 91.3% of revenue for MREO, versus a peer median of 4.6%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
LXEOLexeo Therapeutics, Inc. Common Stock | LTM Mar 2026 | $8.3M USD | -220.6% | +54.2% | — |
| LTM Mar 2026 | $5.6M USD | — | — | 608.1% | |
| LTM Mar 2026 | $3.03M USD | +109.0% | -7.1% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $2.21M USD | -172.7% | +55.8% | — |
| LTM Mar 2026 | $1.99M USD | +632.7% | — | — | |
| LTM Mar 2026 | $1.59M USD | -99.4% | +70.5% | — | |
| LTM Mar 2026 | $456.35K USD | +226.0% | — | 91.3% | |
| LTM Dec 2025 | CHF 327.34K CHF | — | — | 9.2% | |
| LTM Mar 2026 | $204.79K USD | -411.0% | -70.8% | — | |
| LTM Mar 2026 | €0 EUR | — | — | 0.0% | |
| FY2025 | A$0 AUD | — | — | 0.0% | |
| Peer median (excluding MREO) | — | -136.1% | +54.2% | 4.6% | |
Competitors are the stored peer set for MREO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | 19.22M | (42.22M) | (29.47M) | (43.25M) | (41.88M) |
| Depreciation & Amortization | 866.47K | 889K | 1.06M | 1.09M | 622K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 4.46M | 4.77M | 4.92M | 7.39M | 7.6M |
| Change in Working Capital | (2.49M) | (2.35M) | (1.59M) | (369K) | (3.21M) |
| Accounts Receivables | (794.94K) | (3.47M) | 456K | (1.65M) | 1.4M |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 617K | (1.26M) | 146K | (1.38M) |
| Other Working Capital | (1.7M) | 498K | (786K) | 1.13M | (3.23M) |
| Other Non-Cash Items | (29.12M) | (9.91M) | 3.94M | 2.31M | 5.9M |
| Operating Cash Flow | (7.07M) | (48.82M) | (21.13M) | (32.83M) | (30.97M) |
| Capital Expenditures | (722.06K) | (13K) | (419K) | (699K) | (20K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 153.86K | 2M | (419K) | 0 | 0 |
| Investing Cash Flow | (568.2K) | 1.99M | (419K) | (699K) | (20K) |
| Debt Repayment | (933.95K) | 0 | (3.19M) | 0 | 0 |
| Common Stock Issued | 105.99M | 0 | 11.61M | 47M | 327.76K |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | 0 |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (253.73K) | 200K | 24K | (853K) | (764) |
| Financing Cash Flow | 104.8M | 200K | 7.97M | 46.15M | 327K |
| Effect of Forex Changes | (1.57M) | (12.58M) | 2.82M | (233K) | 1.93M |
| Net Change in Cash | 95.59M | (59.22M) | (10.76M) | 12.38M | (28.81M) |
| Free Cash Flow | (7.79M) | (48.83M) | (21.55M) | (33.53M) | (30.99M) |
Mereo BioPharma Group plc
NASDAQ:MREO
Intrinsic Alpha fair value
Locked
Current Price
$0.32
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.